News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
OncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021
25 March 2022
OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan
11 March 2022
OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board
31 January 2022
OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer
27 January 2022
OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members
14 January 2022
OncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms
19 August 2021